Starton Therapeutics has initiated patient dosing in a Phase 2a clinical trial evaluating STAR-LLD, a continuous subcutaneous delivery formulation of lenalidomide intended for patients with relapsed or refractory multiple myeloma. The trial represents a clinical advancement for the company's drug delivery platform, which aims to offer an alternative administration method to the oral formulation currently available as Revlimid.
The study will enroll up to 24 patients with a built-in expansion option to 69 patients, comparing three different dose levels of STAR-LLD against the standard oral Revlimid treatment. The trial is being conducted across six investigational sites throughout the United States, demonstrating expanded clinical infrastructure since the program's initiation. The company expects to complete enrollment during the first half of 2027, positioning the trial for potential data readout in subsequent periods.
The Phase 2a progression marks a key milestone in Starton's clinical pipeline and reflects growing industry interest in alternative delivery mechanisms for established oncology therapeutics. The trial design, which includes dose-ranging comparisons, will provide data relevant to the efficacy and safety profile of the subcutaneous formulation relative to existing standard-of-care treatment options.